Fresenius Medical Care AG ADR (FMS) — Titan Protect Analysis

FMS

Fresenius Medical Care AG ADR

Healthcare · ·

$22.03

Data: 2026-06-03

✓ ETHICAL PASS

NARROW MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$11.2B

Total market value of the company

Trailing P/E

10.98

Reasonably valued

Forward P/E

5.31

Based on estimated future earnings — lower means cheaper

Rev Growth

-5.5%

Year-over-year revenue change

Profit Margin

4.9%

How much profit the company keeps from each dollar of revenue

ROE

7.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$25.94

+18% from current price — median analyst estimate

Recommendation

HOLD

Consensus view from 7 analysts covering this stock

About Fresenius Medical Care AG ADR

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract

https://www.freseniusmedicalcare.com

Country: Germany Employees: 108,165 Industry: Medical Care Facilities

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.322

Positive but modest risk-adjusted returns

Kelly Fraction

0.0180

Marginal edge — very small allocation suggested

Calmar Ratio

0.165

Drawdown risk outweighs the returns — higher risk profile

Annual Return

5.2%

Historical annualised return based on price data

Max Drawdown

-31.5%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.82

Less volatile than the market — more defensive

52W High

$29.07

24% below the year high

52W Low

$20.02

10% above the year low

Avg Volume

706,253

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

424.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$1.90

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

77.75

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

26.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

8.1%

Profit from core operations before interest and tax

Free Cash Flow

$1.7B

Positive — the business generates more cash than it spends

Revenue (TTM)

$19.4B

Total revenue over the last 12 months

Net Income

$945M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$37.93

Target Median

$25.94

Target Low

$17.94

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go